---
title: "Novartis AG (NVS.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NVS.US/overview.md"
symbol: "NVS.US"
name: "Novartis AG"
parent: "https://longbridge.com/en/quote/NVS.US.md"
datetime: "2026-04-05T11:04:26.380Z"
locales:
  - [en](https://longbridge.com/en/quote/NVS.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NVS.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NVS.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/NVS.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NVS.US/overview.md)


# Novartis AG (NVS.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Address | Lichtstrasse 35, Basel, Basel-Stadt, Switzerland |
| Website | [www.novartis.com](https://www.novartis.com) |

## Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.

## Key Executives

| Name | Title |
|------|-------|
| Vasant Narasimhan | Chief Executive Officer |
| Giovanni Caforio | Independent Chairman of the Board |
| Victor Bulto | President of US |
| Patrick Horber | President of International |
| Mukul Mehta | Chief Financial Officer |
| Steffen Lang | President of Operations |
| Simon E. Moroney | Independent Vice Chairman of the Board |
| Daniel Luzius Vasella | Honorary Chairman |
| Ton Buechner | Independent Non-Executive Director |
| Elizabeth Doherty | Independent Non-Executive Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| UBS Asset Management (Americas) LLC | 7.32% | 2024-09-30 |
| UBS Asset Management AG | 6.15% | 2025-12-31 |
| The Vanguard Group, Inc. | 4.73% | 2026-02-28 |
| Sandoz Family Office SA | 4.71% | 2024-12-31 |
| Norges Bank Investment Management | 2.42% | 2025-12-31 |
| Dodge & Cox | 1.11% | 2025-12-31 |
| GQG Partners LLC | 0.93% | 2026-01-31 |
| Geode Capital Management, LLC | 0.92% | 2026-02-28 |
| Artisan Partners Limited Partnership | 0.82% | 2025-12-31 |
| Deutsche Asset & Wealth Management | 0.67% | 2026-01-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Innovative Medicines | 56674000000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Novartis AG Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Innovative Medicines",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 23331000000 | 42.78% |
| Other | 21684000000 | 39.76% |
| China | 4188000000 | 7.68% |
| Germany | 3935000000 | 7.22% |
| Switzerland | 1394000000 | 2.56% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**